Agreements - Novartis (Details)	1 Months Ended						3 Months Ended										6 Months Ended		12 Months Ended					18 Months Ended	39 Months Ended
	May 31, 2015 USD ($)	Jan. 31, 2015 USD ($)	Oct. 31, 2014 USD ($) item	Nov. 30, 2013 USD ($)	Oct. 31, 2013 USD ($)	Mar. 31, 2013 USD ($) item	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Dec. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Dec. 31, 2010 USD ($) item	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Collaborative Agreements disclosures
Amount of arrangement consideration included in license and milestone fees							$ 5,076,000	$ 76,000	$ 76,000	$ 10,077,000	$ 10,692,000	$ 6,070,000	$ 5,086,000	$ 5,078,000	$ 41,417,000	$ 6,234,000	$ 5,152,000	$ 16,762,000	$ 26,915,000	$ 57,815,000	$ 39,455,000
Costs related to the research and development services							33,657,000	$ 32,909,000	$ 38,652,000	$ 36,094,000	$ 38,199,000	$ 35,132,000	$ 30,437,000	$ 25,666,000	$ 27,647,000	$ 28,018,000	$ 66,566,000	$ 73,331,000	148,077,000	111,768,000	106,958,000
Novartis
Collaborative Agreements disclosures
Number of single-target licenses | item			3			1											5						6
Number of related targets | item						2											2
Payments received under collaboration agreement					$ 5,000,000																		$ 45,000,000		$ 60,200,000
License exercise fee			$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000																	1,000,000
Potential milestone payments			$ 199,500,000			199,500,000																	$ 199,500,000
Term of agreement					1 year																		3 years
Potential milestone payments under second option						$ 238,000,000
Estimated utilization period after commercialization																	10 years
Discount rate (as a percent)																	16.00%
Amount of arrangement consideration included in license and milestone fees																				25,700,000	17,200,000	$ 11,100,000
Cumulative catch-up amount included in license and milestone fees																					1,000,000
Estimated term of development and commercialization license						25 years
Costs related to the research and development services																	$ 17,000		$ 67,000	141,000	1,400,000
Costs related to clinical materials sold																				$ 644,000	$ 1,300,000			$ 0
Payments received under collaboration agreement in connection with amended agreement						$ 3,500,000
Novartis | Development milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 5,000,000	$ 5,000,000																							55,000,000
Potential milestone payments						22,500,000																	$ 22,500,000
Potential milestone payments under second option						22,500,000
Novartis | Phase I clinical trial
Collaborative Agreements disclosures
Potential milestone payments							5,000,000										$ 5,000,000							5,000,000	5,000,000
Novartis | Phase II clinical trial
Collaborative Agreements disclosures
Number of single-target licenses | item																	3
Potential milestone payments							$ 7,500,000										$ 7,500,000							$ 7,500,000	7,500,000
Novartis | Future Technological Improvements
Collaborative Agreements disclosures
Payments received under collaboration agreement																									4,500,000
Novartis | Research Services
Collaborative Agreements disclosures
Payments received under collaboration agreement																									$ 710,000
Potential milestone payments under second option						115,500,000
Novartis | Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments						77,000,000																	77,000,000
Novartis | Sales milestones
Collaborative Agreements disclosures
Potential milestone payments						100,000,000																	$ 100,000,000
Potential milestone payments under second option						$ 100,000,000